Nuformix (FRA:1RT) Research & Development: €0.00 Mil (TTM As of Mar. 2026)


What is Nuformix Research & Development?

Nuformix FRA:1RT Research & Development is €0.00 Mil as of Mar. 2026. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Nuformix's Research & Development for the six months ended in Mar. 2026 was €0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €0.00 Mil.

Nuformix  (FRA:1RT) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Nuformix Research & Development Related Terms

Nuformix Research & Development Historical Data

* Premium members only.

The historical data trend for Nuformix's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nuformix Research & Development Chart

Nuformix Annual Data
Trend Dec15 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Sep24 Sep25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Nuformix Semi-Annual Data
Dec15 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Mar24 Sep24 Mar25 Sep25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Nuformix Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0.00 Mil mean?
Nuformix (FRA:1RT) has a Research & Development of €0.00 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Nuformix and its competitors.
Is Nuformix's Research & Development too high?
Nuformix's current Research & Development is €0.00 Mil.
How does Nuformix's Research & Development compare to VRTX and REGN?
Nuformix's Research & Development of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Nuformix and its competitors. Nuformix's current Research & Development is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nuformix stock overvalued right now?
Nuformix (FRA:1RT) has a current Research & Development of €0.00 Mil. The current Research & Development is €0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Nuformix (FRA:1RT), the current Research & Development is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nuformix Business Description

Other Exchanges NFX:UK1RT:Germany
Address C/O Arch Law Limited, 8 Bishopsgate, Huckletree Bishopsgate, London, GBR, EC2N 4BQ
Nuformix PLC is a pharmaceutical development company. It operates in pharmaceutical development, targeting unmet medical needs in fibrosis and oncology through drug repurposing. Its pipeline products include NXP001, NXP002, and NXP004. Geographically, the company operates only in the UK.